ACADIA Pharmaceuticals shares are trading higher after the company announced it acquired ex-North American rights to trofinetide and global rights to Neuren's NNZ-2591 in Rett Syndrome and Fragile X syndrome. The company also announced guidance.
Portfolio Pulse from Benzinga Newsdesk
ACADIA Pharmaceuticals has acquired ex-North American rights to trofinetide and global rights to Neuren's NNZ-2591 in Rett Syndrome and Fragile X syndrome. The company also announced guidance.

July 14, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ACADIA Pharmaceuticals has acquired rights to new drugs, which could potentially increase its product portfolio and revenue in the future.
The acquisition of rights to new drugs expands ACADIA's product portfolio, potentially leading to increased revenue and growth. This is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100